143 related articles for article (PubMed ID: 18639380)
1. Effect of sertindole on QTc interval in patients with schizophrenia.
Atmaca M; Yavuzkir M; Mermi O; Topuz M; Kanmaz E; Tezcan E
Neurosci Lett; 2008 Sep; 442(1):1-3. PubMed ID: 18639380
[TBL] [Abstract][Full Text] [Related]
2. The effect of sertindole on QTD and TPTE.
Nielsen J; Andersen MP; Graff C; Kanters JK; Hardahl T; Dybbro J; Struijk JJ; Meyer JM; Toft E
Acta Psychiatr Scand; 2010 May; 121(5):385-8. PubMed ID: 20085555
[TBL] [Abstract][Full Text] [Related]
3. Sertindole causes distinct electrocardiographic T-wave morphology changes.
Nielsen J; Graff C; Hardahl T; Andersen MP; Kristoffersen J; Struijk JJ; Toft E; Meyer JM
Eur Neuropsychopharmacol; 2009 Oct; 19(10):702-7. PubMed ID: 19457646
[TBL] [Abstract][Full Text] [Related]
4. Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia.
Nielsen J; Matz J; Mittoux A; Polcwiartek C; Struijk JJ; Toft E; Kanters JK; Graff C
Eur Neuropsychopharmacol; 2015 Mar; 25(3):303-11. PubMed ID: 25583364
[TBL] [Abstract][Full Text] [Related]
5. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.
Lindström E; Farde L; Eberhard J; Haverkamp W
Int J Neuropsychopharmacol; 2005 Dec; 8(4):615-29. PubMed ID: 15963244
[TBL] [Abstract][Full Text] [Related]
6. Drug safety and efficacy evaluation of sertindole for schizophrenia.
Karamatskos E; Lambert M; Mulert C; Naber D
Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
[TBL] [Abstract][Full Text] [Related]
7. Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
Prescrire Int; 2007 Apr; 16(88):59-62. PubMed ID: 17458045
[TBL] [Abstract][Full Text] [Related]
8. Sertindole in the long-term treatment of schizophrenia.
Hale AS; Azorin JM; Lemming OM; Mæhlum E
Int Clin Psychopharmacol; 2012 Jul; 27(4):231-7. PubMed ID: 22609816
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.
Wilton LV; Heeley EL; Pickering RM; Shakir SA
J Psychopharmacol; 2001 Jun; 15(2):120-6. PubMed ID: 11448085
[TBL] [Abstract][Full Text] [Related]
11. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
[TBL] [Abstract][Full Text] [Related]
12. Do we need another atypical antipsychotic?
Kasper S
Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242
[TBL] [Abstract][Full Text] [Related]
13. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy.
Wehnert A
Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S27-30. PubMed ID: 9690967
[TBL] [Abstract][Full Text] [Related]
14. Sertindole: dilemmas for its use in clinical practice.
Pae CU
Expert Opin Drug Saf; 2013 May; 12(3):321-6. PubMed ID: 23432404
[TBL] [Abstract][Full Text] [Related]
15. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
Thomas SH; Drici MD; Hall GC; Crocq MA; Everitt B; Lader MH; Le Jeunne C; Naber D; Priori S; Sturkenboom M; Thibaut F; Peuskens J; Mittoux A; Tanghøj P; Toumi M; Moore ND; Mann RD
Acta Psychiatr Scand; 2010 Nov; 122(5):345-55. PubMed ID: 20384598
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of QT interval in patients treated with psychotropic drugs.
Novotny T; Florianova A; Ceskova E; Weislamplova M; Palensky V; Tomanova J; Sisakova M; Toman O; Spinar J
Int J Cardiol; 2007 May; 117(3):329-32. PubMed ID: 16863665
[TBL] [Abstract][Full Text] [Related]
17. Ejaculatory dysfunction in patient with schizophrenia on sertindole.
Jukić MK; Drmić S; Mimica N
Psychiatr Danub; 2010 Mar; 22(1):128-31. PubMed ID: 20305609
[TBL] [Abstract][Full Text] [Related]
18. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe.
Lançon C; Toumi M; Sapin C; Hansen K
BMC Psychiatry; 2008 Jul; 8():57. PubMed ID: 18638382
[TBL] [Abstract][Full Text] [Related]
19. Sertindole for the treatment of schizophrenia.
Azorin JM; Kaladjian A; Fakra E; Adida M
Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.
Kwon JS; Mittoux A; Hwang JY; Ong A; Cai ZJ; Su TP
Int Clin Psychopharmacol; 2012 Nov; 27(6):326-35. PubMed ID: 22850268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
